Skip to content
lifestyle.pluralist.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Protagenic Therapeutics, Inc.
Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in Generalized Anxiety Disorder
August 20, 2026
Protagenic Therapeutics’ Lead Candidate PT00114 Attenuated Chronic Stress Responses in a Well-Established Rodent Model
June 30, 2026
Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner
May 19, 2026
Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114
April 23, 2026
Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114
March 17, 2026
Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market
March 10, 2026